Open AccessClostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
Author(s) -
Shaleen Vasavada,
Kavea Panneerselvam,
Rajan Amin,
Krishnavathana Varatharajalu,
Pablo C. Okhuysen,
Isabella C. Glitza Oliva,
Jianbo Wang,
Petros Grivas,
Anusha Shirwaikar Thomas,
Yinghong Wang
Publication year - 2022
Publication title -
annals of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.886
H-Index - 33
eISSN - 1792-7463
pISSN - 1108-7471
DOI - 10.20524/aog.2022.0722
Subject(s) - medicine , antibiotics , diarrhea , context (archaeology) , gastroenterology , cancer , clostridioides , immunology , microbiology and biotechnology , paleontology , biology
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but are associated with immune-mediated diarrhea and colitis (IMDC). Clostridioides difficile infection (CDI) can cause infectious diarrhea with overlapping symptoms. Thus, we sought to elucidate the characteristics of CDI in patients treated with ICI, in the context of IMDC.